Boehringer Ingelheim’s Pradaxa Will Garner Blockbuster Sales of $1.3 Billion by 2018 in the Atrial Fibrillation Drug Market

Positive Results From the RE-LY Clinical Trial Will Help Drive Pradaxa's Uptake, According to New Findings from Decision Resources WALTHAM, Mass., March 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Boehringer Ingelheim's Pradaxa will become one of the leading stroke prevention therapies in the atrial fibrillation drug market, garnering blockbuster sales of $1.3 billion by 2018 in the United...

Heart attacks peak during winter months, finds research

Research has found that heart attacks peak during the winter months, and the prevailing hypothesis has been that cold temperatures stress the heart. But in 2004, researchers analyzed 12 years of Los Angeles County death certificates and found that heart attack deaths also rise in the balmy Los Angeles...

Common Heart Rhythm Problem on the Rise in the U.S.

About 3 million Americans suffer from the most common type of abnormal heart rhythm, atrial fibrillation, and that number is likely to double by 2035, new research...